Efficacy and safety of deucravacitinib up to week 52 in the POETYK PsA-2 study •ACR20 at W16: 54.2% (deucravacitinib) vs 39.4% (placebo), p=0.0002 •PASI75: 40.9% vs 15.4%, p<0.0001 •MDA: 25.6% vs 14.7%, p=0.0007 •FACIT-F: +2.5 vs +1.8 •SAE: 1.9% (low) TYK2 inhibition shows https://t.co/JXTZRk2itA

❓️Is early intensive therapy with combination csDMARDs or TNFi superior to standard step care for the treatment of moderate to severe #psoriatic_arthritis? 🅰️ Yes 🔅Check out the SPEED RCT presented by @DrLauraCoates at #EULAR2025 OP0089 @RheumNow #Strategy https://t.co/24e7wUV2FB

#EULAR2025 Abstr#OP0078 #Lupus nephritis is assoc with CVD. Propensity matched analysis comparing GLP-1 agonist vs SLGT2-i using TrinetX database in LN ->favourable risk reduction with GLP-1: -CKD progression -Mortality -MI Validation & mechanistic explanation needed @RheumNow https://t.co/xPDVDm1CHm

In propensity-matched RA cohort (n=2,449 each) on JAK inhibitors, adding a GLP-1 agonist reduced risk of: • Acute coronary syndromes (RR 0.65, p=0.0009) • DVT (RR 0.69, p=0.007) Overall CV events ↓ by 33% (RR 0.67, p=0.0007) #EULAR2025 @RheumNow Abstract#OP0069 https://t.co/jWI6tvri8O

Can RA be intercepted? In the ALTO follow-up of the APIPPRA RCT (Cope et al), 1 year of abatacept delayed RA onset by up to 3 years in ACPA+/RF+ individuals. Effect strongest in those with mature autoantibody profiles. Abstract#OP0004 @RheumNow #EULAR2025 https://t.co/N7YwtYod8w

Repurposing drugs to #osteoarthritis No jewel in the rough! Most drugs - MTX, colchicine, TNFi, IL1i, etc are NEGATIVE or yield mixed results from diff #RCTs Not sure this is the way forward for #OA drug discovery 💡 #EULAR2025 @RheumNow @eular_org Abst#POS565 https://t.co/A6SdXtOo7v

RA pts have ↑ risk of DVT (HR 2.26) & PE (HR 1.61) vs controls in this 40-year, pop-based study. Nodules, obesity, high disease activity & early biologic use ↑ risk. Remission in year 1 halved PE risk. VTE risk persists despite therapeutic advances. @RheumNow #EULAR2025 #OP0070 https://t.co/AaBi2o2cUw

GI symptoms in axSpA -Cohort of 370 pts with axSpAfrom New Zealand -Elevated fecal calprotectin ➡️ positive correlation with GI symptoms and high disease activity -Bowel symptoms associated with reduced quality of life. -Use of TNFi improved bowel symptoms over time. https://t.co/wA37G3HWyi

IL-17 inhibition for PMR? In the secukinumab ph2 in GCA (TitAIN), patients with PMR did really well, seemingly outperforming steroid taper in the placebo arm. Real promise, will be great to see how the ph3 in PMR (REPLENISH) goes OP0062 #EULAR2025 @RheumNow https://t.co/cisA0GiUx1

MONITOR PsA 200+ pts secondary care "real-life" cohort 65 treated w/ combi csDMARDs 48weeks outcome and 96 weeks 49% bioDMARDs, 29% retention and 23% deescalation to 1 csDMARD ‼️reasons for discontinuation was AEs in 60% cases not inefficacy Caveat: analysis not adjusted for https://t.co/L8EczgZTpP

RA polygenic risk ≠ MI risk. In >8,700 Swedes w/ or w/o RA, higher genetic risk for RA wasn’t linked to higher MI incidence. Familial clustering of RA & MI likely driven by non-genetic factors. Traditional CV risk still key in RA care. @RheumNow #EULAR2025 #OP0072 https://t.co/KN6Dg0ekt2